I believe the roll out of the Reata drug is a lot slower than DAYBUE which is very comforting…
Because of a manufacturing hitch, there was a delay in the US Skyclarys launch until late June last year, two months after DayBue’s launch.
Since then, Skyclarys has received approval in the EU (February 2024) and has already been filed for approval in Australia (May 2024). Q1 2024 sales were US$78m, slightly beating DayBue sales for the quarter of US$75.9m.
I believe the roll out of the Reata drug is a lot slower than...
-
- There are more pages in this discussion • 526 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.75 |
Change
0.160(1.03%) |
Mkt cap ! $2.013B | |||
| Open | High | Low | Value | Volume |
| $15.68 | $16.08 | $15.32 | $5.559M | 351.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 926 | $15.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.88 | 1993 | 1 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |